文献速递临床试验与 GCP流行病学与生物统计

羟氯喹预防孕妇SARS-CoV-2感染及COVID-19严重程度的研究方案结构化摘要

Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
PubMed 文献 · Trials · 2020-07-02

本研究为随机双盲安慰剂对照多中心临床试验,旨在评估羟氯喹在孕妇中减少SARS-CoV-2病毒排毒、预防感染及防止无症状感染者发展为COVID-19的疗效与安全性。计划纳入200例SARS-CoV-2感染孕妇和514例密切接触孕妇,随机1:1接受14天口服羟氯喹或安慰剂,主要终点为治疗开始后第21天PCR确诊感染孕妇数。

要点

  • 评估羟氯喹对孕妇SARS-CoV-2病毒排毒、感染预防及疾病进展的作用。
  • 随机双盲安慰剂对照,14天口服方案,主要终点为第21天PCR确诊感染。
  • 计划纳入200例感染孕妇和514例接触孕妇,1:1随机分组。

核心结论

  • 研究旨在评估羟氯喹在孕妇中预防SARS-CoV-2感染和降低COVID-19疾病严重程度的疗效与安全性。

研究设计与样本

  • 随机双盲安慰剂对照两臂多中心临床试验,在西班牙5家医院开展。
  • 计划纳入200例SARS-CoV-2感染孕妇(症状性100例、无症状100例)和514例PCR阴性密切接触孕妇。
  • 参与者按1:1随机接受14天口服羟氯喹或安慰剂治疗。

关键数值与推荐

  • 羟氯喹剂量为400 mg/天×3天,随后200 mg/天×11天;安慰剂为2片×3天,随后1片×11天。
  • 主要结局为治疗开始后第21天(治疗完成后一周)鼻咽和口咽拭子PCR确诊感染的孕妇数。
  • 纳入标准包括孕周>12周(超声核实)、发热≥37.5°C和/或一种COVID-19轻症症状,或14天内与确诊/疑似病例密切接触。
  • 排除标准包括羟氯喹过敏史、视网膜病变史、合并使用地高辛/环孢素/西咪替丁、肝病、心脏病理史(含长QT综合征)等。

临床怎么用

  • 该方案为评估羟氯喹在孕妇中预防COVID-19的随机对照试验设计,结果待报告。

局限性

  • 原文为研究方案摘要,尚未报告疗效和安全性结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The primary objectives of the study are: 1. To assess the effect of hydroxychloroquine (HCQ) in reducing SARS-CoV-2 viral shedding by PCR in infected pregnant women with mild symptoms. 2. To assess the efficacy of HCQ to prevent SARS-CoV-2 infection in pregnant women in contact with an infected or suspected case. 3. To evaluate the effect of HCQ in preventing the development of the COVID-19 disease in asymptomatic SARS-CoV-2-infected pregnant women. The secondary objectives are: 1. To determine the effect of HCQ on the clinical course and duration of the COVID-19 disease in SARS-CoV-2-infected pregnant women. 2. To determine the impact of HCQ on the risk of hospitalization and mortality of SARS-CoV-2-infected pregnant women. 3. To assess the safety and tolerability of HCQ in pregnant women. 4. To describe the clinical presentation of SARS-CoV-2 infection during pregnancy. 5. To describe the effects of maternal SARS-CoV-2 infection on pregnancy and perinatal outcomes by treatment group. 6. To determine the risk of vertical transmission (intra-utero and intra-partum) of SARS-CoV-2. TRIAL DESIGN: Randomized double-blind placebo-controlled two-arm multicentre clinical trial to evaluate the safety and efficacy of HCQ to prevent and/or minimize SARS-CoV-2 infection during pregnancy. Participants will be randomized to receive a 14-day oral treatment course of HCQ or placebo, ratio 1:1. PARTICIPANTS: Study population: pregnant women undergoing routine prenatal follow up or attending emergency units at the participating hospitals who report either symptoms/signs suggestive of COVID-19 disease or close contact with a suspected or confirmed COVID-19 case. Inclusion criteria Women will be invited to participate in the trial and sign an informed consent if they meet the following inclusion criteria. • Presenting with fever (≥37.5°C) and/or one mild symptom suggestive of COVID-19 disease (cough, dyspnoea, chills, odynophagia, diarrhoea, muscle pain, anosmia, dysgeusia, headache) OR being contact* of a SARS-CoV-2 confirmed or suspected case in the past 14 days • More than 12 weeks of gestation (dated by ultrasonography) • Agreement to deliver in the study hospitals Exclusion criteria • Known hypersensitivity to HCQ or other 4-amonoquinoline compounds • History of retinopathy of any aetiology • Concomitant use of digoxin, cyclosporine, cimetidine • Known liver disease • Clinical history of cardiac pathology including known long QT syndrome • Unable to cooperate with the requirements of the study • Participating in other intervention studies • Delivery onset (characterized by painful uterine contractions and variable changes of the cervix, including some degree of effacement and slower progression of dilatation up to 5 cm for first and subsequent labours) The study participants will be stratified by clinical presentation and SARS-CoV-2 PCR results. Assignment of participants to study groups will be as follows: • SARS-CoV-2-PCR confirmed, infected pregnant women: a. symptomatic (n=100) b. asymptomatic (n=100) • SARS-CoV-2 PCR negative pregnant women in contact* with a SARS-CoV-2-infected confirmed or suspected case (n=514). *The ECDC definition of close contact will be followed. The trial will be conducted in five hospitals in Spain: Hospital Clínic of Barcelona, Hospital Sant Joan de Déu and Hospital de la Santa Creu i Sant Pau, in Barcelona, and HM Puerta del Sur and Hospital Universitario de Torrejón, in Madrid. INTERVENTION AND COMPARATOR: Participants will be randomized to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days) or placebo (2 tablets for three days, followed by one tablet for 11 days). MAIN OUTCOMES: The primary outcome is the number of PCR-confirmed infected pregnant women assessed from collected nasopharyngeal and oropharyngeal swabs at day 21 after treatment start (one week after treatment is completed). RANDOMISATION: Allocation of participants to study arms will be done centrally by the trial's Sponsor (the Barcelona Institute for Global Health, ISGlobal) by block randomization. This method will ensure balanced allocation to both arms. The electronic CRF will automatically assign a study number to each participant, depending on her study group and recruitment site. Each number will be related to a treatment number, which assigns them to one of the study arms. BLINDING (MASKING): Participants, caregivers, investigators and those assessing the outcomes will be blinded to group assignment. Study tablets (HCQ and placebo) will be identically packaged in small opaque bottles. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): This study requires 200 SARS-CoV-2 infected and 514 contact pregnant women, randomised 1:1 with 100 and 227 respectively in each study arm. TRIAL STATUS: Protocol version 1.0, from May 8th, 2020. Recruitment is ongoing (first patient recruited the 19th May 2020 and recruitment end anticipated by December 2020). TRIAL REGISTRATION: EudraCT number: 2020-001587-29, registered 2 April 2020. Clinicaltrials.gov identifier: NCT04410562 , retrospectively registered 1 June 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. González R, García-Otero L, Pons-Duran C, et al. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial. Trials. 2020. PMID: 32616063. doi:10.1186/s13063-020-04557-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。